Study to Evaluate the Safety and Tolerability of EP0042

A research study looking at a new treatment for patients with advanced cancer, to investigate different doses of the experimental study drug, EP0042, in order to determine a dose, which is safe, well-tolerated and likely to be effective in treating AML (acute myeloid leukaemia).

Trial Details

NCT ID
NCT04581512
Phase
PHASE1 / PHASE2
Sponsor
Ellipses Pharma
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • EP0042
  • Venetoclax
  • Azacitidine (AZA)
Locations (sample)
  • Perth, Western Australia, Australia|-31.95224,115.8614
  • Amsterdam, Netherlands|52.37403,4.88969
  • Rotterdam, Netherlands|51.9225,4.47917
  • London, UK, United Kingdom|51.50853,-0.12574
  • London, United Kingdom|51.50853,-0.12574

Key Eligibility Criteria

  • Male or female patients aged ≥ 18 years of age, at the time of informed consent, with histological or cytological confirmation of AML
  • Ability to understand and provide written informed consent before any study-specific procedures, sampling, or analyses, including access to archiva…
  • Ability to swallow and retain oral medication
  • Sufficient life expectancy to allow the patient to complete at least 1 cycle (28 days) of the treatment period.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →